Truist lowered the firm’s price target on Evolent Health (EVH) to $6 from $10 and keeps a Buy rating on the shares following a post-quarterly call with management to discuss Q4 results, the 2026 outlook and cost trends.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EVH:
- Midday Fly By: Workday, Lowe’s in focus after earnings
- Balancing Near-Term Execution Risk With Long-Term EBITDA Upside: Why Evolent Remains a Buy Despite a Lowered Target
- Evolent Health price target lowered to $8 from $10 at BTIG
- Evolent Health price target lowered to $4 from $9 at Canaccord
- Evolent Health: Conservative Guidance and Elevated Reserves Set the Stage for 2026 Margin Upside and Support a Buy Rating